Ocugen published positive Phase 1 GARDian1 trial results for OCU410ST, a gene therapy for Stargardt disease, in the peer-reviewed journal Nature Eye. The trial showed reduced atrophic lesion growth, slower lesion expansion, and improved visual acuity in treated eyes compared to untreated eyes over 12 months. Stargardt disease affects over 100,000 people in the US and Europe with no approved treatment. The Phase 2/3 GARDian3 trial is ahead of schedule, with enrollment expected to be completed in early 2026, positioning Ocugen for a Biologics License Application filing in the first half of 2027.

Read more at GlobeNewswire: Ocugen Announces Publication of Phase 1 GARDian1 Trial